We are live on ! Find out more

Protalix BioTherapeutics

PLX

Market cap $213M

2.64 USD

-0.09

3.3%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

2.72

+0.08

3.03%

1 day

-3.3%

5 days

0.76%

1 month

8.64%

3 months

28.78%

6 months

-8.65%

Year to date

51.72%

1 year

51.72%

5 years

80.82%

10 years

-58.1%

About: Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Employees: 226

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

CARMIEL, Israel, Sept. 8, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York: H.C.

Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio® Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone payment Year-to-date, the Company achieved profitability with a net income of $22.1 million The Company reiterates full-year 2026 guidance of $78.0 million to $83.0 million in total revenue PRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027 Cash, cash equivalents, and short-term bank deposits were $40.7 million as of June 30, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115 CARMIEL, Israel, Aug. 12, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the second quarter ended June 30, 2026, and provided a business and clinical update.

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, Aug. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended June 30, 2026 and provide a business update on August 12, 2026.

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027 The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115 CARMIEL, Israel, May 13, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the first quarter ended March 31, 2026, and provided a business and clinical update.

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended March 31, 2026 and provide a business update on May 13, 2026.

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

Protalix BioTherapeutics reported weaker FY25 results but issued robust FY26 revenue guidance of $78–83 million, well above consensus. PLX's growth thesis centers on Elfabrio's EU approval and once-every-4-weeks dosing, offering a clear competitive and patient adherence advantage. Chiesi's contribution is expected to exceed 50% revenue growth in 2026, improving margin mix and earnings predictability despite near-term volatility.

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript

Proactive Investors

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regulatory, clinical and commercial developments, including a new European approval for its Fabry disease therapy and updated guidance for 2026. "2025 was a year of meaningful progress for Protalix, marked by strong commercial execution with our partners and important advances and strategic direction across our clinical and preclinical pipeline," the company's CEO Dror Bashan said.

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025

See News Rankings

Price charts implemented using Lightweight Charts™